Monte Rosa Therapeutics Statistics
Total Valuation
GLUE has a market cap or net worth of $1.67 billion. The enterprise value is $1.04 billion.
Important Dates
The last earnings date was Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GLUE has 84.48 million shares outstanding. The number of shares has increased by 9.92% in one year.
| Current Share Class | 84.48M |
| Shares Outstanding | 84.48M |
| Shares Change (YoY) | +9.92% |
| Shares Change (QoQ) | +16.76% |
| Owned by Insiders (%) | 0.63% |
| Owned by Institutions (%) | 76.64% |
| Float | 52.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 38.77 |
| Forward PS | 47.28 |
| PB Ratio | 3.18 |
| P/TBV Ratio | 3.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 24.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.54, with a Debt / Equity ratio of 0.07.
| Current Ratio | 9.54 |
| Quick Ratio | 9.44 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -32.62% and return on invested capital (ROIC) is -21.11%.
| Return on Equity (ROE) | -32.62% |
| Return on Assets (ROA) | -16.41% |
| Return on Invested Capital (ROIC) | -21.11% |
| Return on Capital Employed (ROCE) | -22.28% |
| Weighted Average Cost of Capital (WACC) | 12.88% |
| Revenue Per Employee | $229,695 |
| Profits Per Employee | -$695,262 |
| Employee Count | 187 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.87M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +385.47% in the last 52 weeks. The beta is 1.62, so GLUE's price volatility has been higher than the market average.
| Beta (5Y) | 1.62 |
| 52-Week Price Change | +385.47% |
| 50-Day Moving Average | 18.25 |
| 200-Day Moving Average | 14.93 |
| Relative Strength Index (RSI) | 57.33 |
| Average Volume (20 Days) | 770,844 |
Short Selling Information
The latest short interest is 14.96 million, so 17.71% of the outstanding shares have been sold short.
| Short Interest | 14.96M |
| Short Previous Month | 15.14M |
| Short % of Shares Out | 17.71% |
| Short % of Float | 28.26% |
| Short Ratio (days to cover) | 18.67 |
Income Statement
In the last 12 months, GLUE had revenue of $42.95 million and -$130.01 million in losses. Loss per share was -$1.50.
| Revenue | 42.95M |
| Gross Profit | -102.46M |
| Operating Income | -148.28M |
| Pretax Income | -131.88M |
| Net Income | -130.01M |
| EBITDA | -139.94M |
| EBIT | -148.28M |
| Loss Per Share | -$1.50 |
Full Income StatementBalance Sheet
The company has $666.22 million in cash and $39.06 million in debt, with a net cash position of $627.16 million or $7.42 per share.
| Cash & Cash Equivalents | 666.22M |
| Total Debt | 39.06M |
| Net Cash | 627.16M |
| Net Cash Per Share | $7.42 |
| Equity (Book Value) | 521.92M |
| Book Value Per Share | 6.19 |
| Working Capital | 606.51M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.68 million and capital expenditures -$4.98 million, giving a free cash flow of -$19.66 million.
| Operating Cash Flow | -14.68M |
| Capital Expenditures | -4.98M |
| Depreciation & Amortization | 8.34M |
| Net Borrowing | n/a |
| Free Cash Flow | -19.66M |
| FCF Per Share | -$0.23 |
Full Cash Flow StatementMargins
| Gross Margin | -238.54% |
| Operating Margin | -345.21% |
| Pretax Margin | -307.04% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GLUE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.92% |
| Shareholder Yield | -9.92% |
| Earnings Yield | -7.81% |
| FCF Yield | -1.18% |
Analyst Forecast
The average price target for GLUE is $32.33, which is 64.03% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $32.33 |
| Price Target Difference | 64.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 52.54% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GLUE has an Altman Z-Score of 1.42 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.42 |
| Piotroski F-Score | 2 |
